Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

330.97 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 568
Open 330.97
Bid (Size) 331.00 (10)
Ask (Size) 332.66 (4)
Prev. Close 330.97
Today's Range 330.97 - 330.97
52wk Range 276.83 - 384.44
Shares Outstanding N/A
Dividend Yield 1.03%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India. 
Via Benzinga
Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease
 
Via Benzinga

Performance

YTD
-9.32%
-9.32%
1 Month
+1.06%
+1.06%
3 Month
-10.06%
-10.06%
6 Month
+11.63%
+11.63%
1 Year
+16.12%
+16.12%

More News

Read More
7 Healthcare Stocks to Buy for Long-Term Growth and Stability
Via InvestorPlace
Looking At Eli Lilly's Recent Unusual Options Activity
Via Benzinga
Beat the Dow Jones With This Unstoppable Dividend Stock
Via The Motley Fool
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
Peering Into Eli Lilly's Recent Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years
Via Benzinga
This Is What Whales Are Betting On Eli Lilly
Via Benzinga
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
Via Benzinga
Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments
Via Benzinga
Eli Lilly Stock Shows Improved Relative Price Performance; Still Shy Of Benchmark
Via Investor's Business Daily
Novo Nordisk Follows Eli Lilly In Slashing Insulin Prices By 75%
Via Benzinga
Eli Lilly, Hewlett Packard Enterprise And 2 Other Stocks Insiders Are Selling
Via Benzinga
Why Eli Lilly Stock Cruised to a 3% Gain on Monday
Via The Motley Fool
Looking At Eli Lilly's Recent Unusual Options Activity
Via Benzinga
Eli Lilly's Alzheimer's Candidate Was Found No Better Than Placebo, Fails To Prevent Illness
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023
Via Benzinga
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
Via Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
Via Benzinga
A Comprehensive Study Exploring Antibody Services Market : Key Players Eppendorf, Cellab, Cusabio Technology
Via SBWire
Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed
Via Investor's Business Daily
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via TheNewswire.com
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
Via News Direct
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.